Abstract

OVERVIEW OF CONVALESCENT PLASMA THERAPY: CORONA VIRUS(COVID-19)

Nandalwar Pratiksha Ramesh*, Nandakishor B. Bavage, Shyamlila B. Bavage and Gali Vidyasagar

Abstract

disease Corona virus 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel corona virus (2019- nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health., there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Currently there are no vaccines, monoclonal antibodies(mAbs), or drugs available for SARS-CoV-2, although many are in rapid development and some may be available in as hard time. This View point argues the human convalescent serum is an option for prevention and treatment ofCOVID-19disease that could be rapidly available when there are sufficient number so people who have recovered and can donate immunoglobulin-containing serum.

Keywords: Covelescent plasma therapy, benefits, SARS-CoV-2.